Hepatotoxicity due to lysine salt of bendazac.
The lysine salt of bendazac is a non-steroidal anti-inflammatory agent, and it is marketed exclusively for the treatment of cataracts. We report two cases of possible hepatotoxicity due to the use of bendazac lysine. Laboratory tests, serologic tests, abdominal sonography and scan were performed to study liver disease. Reversible increases of the hepatic enzymes were found in both cases. Anemia was also found in one of the cases (case 1). Abnormal liver test results could be related to a possible liver injury attributed to the use of bendazac lysine.